Immuneering Corporation (Nasdaq: IMRX) announced encouraging initial data for its investigational drug, IMM-1-104, in combination with chemotherapy for patients with first-line pancreatic cancer. The announcement coincided with the release of the company's third-quarter 2024 financial results, highlighting a net loss of $14.6 million and R&D expenses of $11.3 million.
The early-stage clinical trial results revealed complete and partial responses in patients treated with IMM-1-104 alongside a modified gemcitabine/nab-paclitaxel regimen. These findings are particularly significant given the historically poor response rates associated with existing therapies for pancreatic cancer.
Regulatory Support for IMM-1-104
In addition to the promising clinical data, Immuneering received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration (FDA) for IMM-1-104 in pancreatic cancer treatment. These designations offer potential benefits such as accelerated approval pathways and market exclusivity.
Ben Zeskind, Ph.D., Co-founder and Chief Executive Officer of Immuneering, stated, "While still early, it is highly encouraging to already see responses – including a complete response – as well as impressive disease control, both at levels that would represent a meaningful improvement over the existing standard of care."
Financial Position and Upcoming Milestones
As of September 30, 2024, Immuneering reported cash, cash equivalents, and marketable securities totaling $50.7 million. The company anticipates that its current cash reserves will be sufficient to fund operations into the fourth quarter of 2025.
Immuneering expects to share initial data from at least one additional arm of the Phase 2a portion of the IMM-1-104 Phase 1/2a trial by the end of the year. Furthermore, initial pharmacokinetic (PK), pharmacodynamic (PD), and safety data from the Phase 1 portion of the IMM-6-415 Phase 1/2a trial are also anticipated by year-end.
About IMM-1-104
IMM-1-104 is an oral, once-daily Deep Cyclic Inhibitor currently in Phase 2a clinical trial for advanced solid tumors, including those with RAS mutations. Immuneering is also developing IMM-6-415, another Deep Cyclic Inhibitor, in a Phase 1/2a trial for advanced solid tumors with RAS or RAF mutations.
